GenMont Biotech (TPE:3164) ROCE %: 8.07% (As of Dec. 2025)


TPE:3164 GenMont Biotech Inc TPE:3164
82 GF Score
Price NT$16.55
GF Value NT$26.24
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is GenMont Biotech ROCE %?

GenMont Biotech TPE:3164 +0.30% 82 ROCE % is 8.07% as of Dec. 2025. GuruFocus rates TPE:3164 with a GF Score™ of 82/100 and a GF Value™ of NT$26.24 (Significantly Undervalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. GenMont Biotech's annualized ROCE % for the quarter that ended in Dec. 2025 was 8.07%.

GenMont Biotech  (TPE:3164) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

GenMont Biotech ROCE % Related Terms

GenMont Biotech ROCE % Historical Data

* Premium members only.

The historical data trend for GenMont Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GenMont Biotech ROCE % Chart

GenMont Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.11 4.33 1.92 4.45 4.36

GenMont Biotech Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.66 5.08 -3.26 8.18 8.07
TPE:3164
82GF Score
GenMont Biotech Inc TPE:3164
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GenMont Biotech ROCE % Calculation

GenMont Biotech's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=67.595/( ( (1708.742 - 140.145) + (1665.083 - 129.779) )/ 2 )
=67.595/( (1568.597+1535.304)/ 2 )
=67.595/1551.9505
=4.36 %

GenMont Biotech's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Sep. 2025 )(Q: Dec. 2025 )
=121.464/( ( (1579.041 - 104.442) + (1665.083 - 129.779) )/ 2 )
=121.464/( ( 1474.599 + 1535.304 )/ 2 )
=121.464/1504.9515
=8.07 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 8.07% mean?
GenMont Biotech (TPE:3164) has a ROCE % of 8.07% as of Dec. 2025.
Is GenMont Biotech's ROCE % too high?
GenMont Biotech's current ROCE % is 8.07%. Overall, GenMont Biotech has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GenMont Biotech's ROCE % compare to VRTX and REGN?
GenMont Biotech's ROCE % of 8.07% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. GenMont Biotech's current ROCE % is 8.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenMont Biotech stock overvalued right now?
Based on GuruFocus' analysis, GenMont Biotech (TPE:3164) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$26.24, compared to a current price of NT$16.55 — trading 36.9% below its estimated fair value. The current ROCE % is 8.07%. GenMont Biotech's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For GenMont Biotech (TPE:3164), the current ROCE % is 8.07% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GenMont Biotech (TPE:3164) Overvalued in 2026?

Based on GuruFocus' analysis, GenMont Biotech stock appears to be undervalued. The current stock price of NT$16.55 is trading 36.9% below its estimated GF Value™ of NT$26.24. GuruFocus considers GenMont Biotech to be Significantly Undervalued.

Key valuation signals for TPE:3164:

  • ROCE %: 8.07%
  • GF Value™: NT$26.24 vs. price of NT$16.55 (36.9% below fair value)
  • GF Score™: 82/100 with 5 warning signs

No single metric tells the full story. See the TPE:3164 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GenMont Biotech Business Description

Address No. 8 Nanke 7th Road, Tainan Science and Technology Park, Shanhua District, Tainan, TWN, 741014
GenMont Biotech Inc is engaged in the research, development, manufacturing, and selling of a variety of probiotic supplements. The Group mainly engages in the manufacturing and selling of functional foods, its single operating segment.
82GF Score

Get the complete analysis for TPE:3164

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$16.55
Price
NT$26.24
GF Value